Mersana Therapeutics, Inc.

Thank you for your patience, and please continue to stand by. The Marsana Therapeutics fourth quarter and year-end 2021 conference call and webcast will begin momentarily. Thank you for your patience, and please continue to stand by. Thank you. Good morning and welcome to Mursana Therapeutics' fourth quarter and year-end 2021 conference call and webcast. Currently, all participants are in listen-only mode. There'll be a question and answer session at the end of this call. I would now like to turn the call over to James Salerno, Associate Director, Investor Relations. Please proceed.

Good morning.

Welcome to Mursana's fourth quarter and year-end 2021 conference call. Earlier today, we issued a press release reviewing our fourth quarter and full-year financial results and business updates, which will be covered on this call. A replay of today's call will also be available on the Investors and Media section of our website. After our prepared remarks, we will open up the call for Q&A. Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws, including with respect to the company's business strategy and the design, progression, and timing of its clinical trials or preclinical studies and the release of data from those studies, the ability of the single-arm uplift cohort to enable registration, the development and potential of our pipeline of innovative ADC candidates, the commercial opportunity of our product candidates, expectations regarding future clinical trial results, including with respect to the timing of the commencement of future disclosures, and the sufficiency of the company's cash on hand and funds available through its debt financing agreement with Oxford Finance and Silicon Valley Bank. Each of these forward-looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected statements. These risks and uncertainties are discussed in the company's quarterly report on Form 10-Q, filed on November 9, 2021, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov and on our website at www.mursana.com. Except as required by law, the company assumes no obligation to update these forward-looking statements publicly even if new information becomes available in the future. With that, I'll turn the call over to Annapurna Papas, Mursana's President and Chief Executive Officer.